Board summary
Key figures
45,192
Registered population
59.8% aged 18–64
19.1%
Aged 65+
ICB 18.8% · England 17.9%
15.8%
Ethnic minority (non-White)
7.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,625
Hypertension register
+12.63% in 3 yrs · England +5.60%
421
SMI register
36.5% of Reigate and Banstead's
643
COPD register
Reviews +10.45% in 3 yrs
Forecast to 2030
9,226
Hypertension patients, 2030
+2,601 on today
57.0%
QRISK ≥20% on statins, 2030
+2.24pp over 3 yrs
6.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
CVD lipid therapy and blood pressure control lag.
QRISK ≥ 20% lipid therapy is 52.2% (England 63.6%) and hypertension control is 67.4% (England 70.3%) despite 90.6% blood pressure recording.
COPD and asthma registers contracted over three years.
From 2023 to 2025, QOF prevalence changed -12.2% for COPD (England +2.6%) and -5.8% for asthma (England +0.5%), which a coding audit could test.
SMI physical health checks and borough inclusion share.
Mental health blood pressure recording rose +25.5 pp to 87.2% (England 83.4%), alongside 49% of the borough learning disability register (397 patients).
Population, age and ethnicity
Older patients reach 19.1% while learning disability prevalence of 0.9% exceeds England
Healthy Horley PCN registers 45,192 patients. Those aged 65+ represent 19.1% (8,616 patients), against 19.4% in Reigate and Banstead, 18.8% in NHS Surrey Heartlands ICB, and 17.9% in England. Patients aged 0-17 account for 21.2% (9,561 patients; LAD 21.0%, ICB 20.4%, England 19.6%). Based on Census usual residents, 84.2% identify as White (LAD 84.4%, ICB 85.3%, England 81.1%) and 7.1% as Asian (LAD 7.5%, ICB 7.7%, England 9.6%). Projected population growth to 2030 is 7.4% under an unverified methodology (LAD 3.2%, ICB 4.9%, England 2.3%). Practice list sizes total 52,403 against the PCN list of 45,192.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Reigate and Banstead local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Reigate and Banstead LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.5% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Reigate and Banstead LA) | 991 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Reigate and Banstead LA) | 8.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Zero registered patients live in Core20 areas; equity work could target inclusion cohorts
Healthy Horley PCN records 0.0% of its 45,192 registered patients in Core20 areas (0 estimated patients). Practice lists total 52,403, yet Modality East Surrey Medical Practice and Wayside Medical Practice both record 0.0% Core20 share, compared with 1.1% in Reigate and Banstead, 0.8% in NHS Surrey Heartlands Integrated Care Board, and 21.0% in England. Average IMD decile is 7.0 (both practices 7.1), above England's 5.5. With zero Core20 concentration and count, inequalities outreach could target inclusion health and clinical cohorts rather than area postcodes.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
421
SMI register
0.93% recorded prevalence
397
Learning disability register
0.88% recorded prevalence
38
Care homes, 809 beds
In the PCN catchment
7.9%
Provide unpaid care
Reigate and Banstead, Census 2021
The PCN records 397 learning disability patients (0.9% prevalence vs 0.6% LAD and England, 0.5% ICB), representing 49% of the borough register, alongside 421 severe mental illness patients (0.9% vs 0.8% LAD and ICB, 1.0% England). Catchment capacity shows 38 care homes with 809 beds. Reigate and Banstead recorded 6 rough sleepers in 2025, with an unpaid carer ceiling estimate of 3,570.
Severe mental illness: physical health checks
SMI prevalence is 0.9% (421 patients). Recorded checks exceed England: blood pressure reached 87.2% (England 83.4%) and BMI reached 84.7% (England 82.1%). However, separate indicator reporting does not confirm comprehensive physical health check completion across the cohort.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,625
Hypertension register
+12.63%
Register growth, 3 yrs
Reigate and Banstead +4.55% · England +5.60%
+4.56pp
BP control, under 80
≤140/90 · −0.22pp aged 80+
+2,601
More patients by 2030
Forecast 9,226 (18.53%)
Hypertension case-finding and control
Hypertension recorded prevalence is 14.6% (6,625 patients), close to Reigate and Banstead (14.0%) and England (15.2%). Recent blood pressure recording reaches 90.6%, above England (90.0%). However, treatment to target trails at 67.4% (England 70.3%, borough 72.0%), including 64.2% in patients aged under 80 (England 67.8%) and 74.8% aged 80+ (England 81.2%), where 3-year change fell 0.3% (England +2.2%). Between practices, treatment to target varies from 52.1% at Wayside Medical Practice to 69.2% at Modality East Surrey Medical Practice. Lower treatment to target than national benchmarks may reflect therapy escalation gaps across practices, which a clinical audit could test.
Lipids and statins
Lipid-lowering therapy uptake lags England across priority cohorts: QRISK ≥ 20% reaches 52.2% (England 63.6%), CKD is 57.0% (England 70.3%), and diabetes with CVD is 77.1% (England 84.4%). Fewer patients receive lipid-lowering therapy than national rates, which systematic statin initiation reviews could address.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 48,345 | £1.90 | £2.24 | £1.86 | £91,856 |
| Cardiovascular (all), 2025 | 77,521 | £4.46 | £4.74 | £3.33 | £345,744 |
In 2026, 48,345 lipid-regulating items were prescribed at £1.90 per item (England £1.86, ICB £2.24), totaling £91,856. The PCN spends £1,934 more than at England's unit cost, but £16,437 less than at NHS Surrey Heartlands Integrated Care Board's unit cost. Prescribing unit costs below the ICB benchmark offer headroom to expand statin therapy.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+8.98%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−5.79%
Asthma prevalence, PCN 3-yr % change
Over three years, COPD prevalence fell 12.2% (England +2.6%; 643 patients, 1.4% vs England 1.9%) and asthma fell 5.8% (England +0.5%; 2,696 patients, 6.3%). Register contraction may reflect coding changes or diagnostic access patterns, which local clinical audits could test. Although the asthma review rate was 69.5% (England 65.7%), about 820 patients lacked an annual review. In youth asthma (aged 6-19), second-hand smoke status recording reached 69.8%, below England (78.8%) and Reigate and Banstead (79.7%).
Cancer register and children's immunisation
The cancer register grew +16.4% over three years (England +9.0%) to 2,080 patients (4.6% vs England 3.8%). In childhood immunisations, age-five MMR dose 1 reached 95.5% (England 91.7%), but dose 2 dropped 4.6 pp to 90.9% (England 82.8%), matching 4-in-1 pre-school booster coverage (90.9%). While above national rates, both age-five boosters trail the 95.0% target by 4.1 pp, highlighting pre-school recall drop-off.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
Across Healthy Horley PCN, recorded cancer prevalence is 4.6% (2,080 patients), rising 16.4% over three years (England +9.0%). Breast screening coverage is 68.5% (Reigate and Banstead 74.6%, England 69.9%) after a three-year rise of 10.3%. Cervical screening in women aged 25–49 is 71.9% (England 66.8%), falling 2.7% over three years (England -1.0%). Across the wider health economy, NHS Surrey Heartlands ICB diagnosed 61.4% of known-stage cancers at stage 1 or 2 in 2022 (known-stage share 67.7%), 13.6 pp below the 75.0% national ambition, representing about 650 extra early-stage cases annually.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At the main acute provider serving the PCN, Surrey and Sussex Healthcare NHS Trust, July 2026 provisional performance achieved 70.0% on the 62-day referral to treatment standard, trailing the 85.0% standard by 15.0 pp and below England at 71.2%. The trust achieved 77.7% on the 28-day faster diagnosis standard (standard 75.0%) and 96.2% on the 31-day combined standard (standard 96.0%). For diagnostics, 28.5% of patients waited 6+ weeks across all diagnostic tests, exceeding England's 23.1%. These figures reflect hospital provider activity rather than direct PCN delivery. Prolonged treatment and diagnostic pathways at the acute provider may increase primary care safety-netting.
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 89.70 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 99.16 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 86.82 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.31 | 21.40 |
| CT | 18.49 | 8.57 | 1.06 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 25.49 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 33.01 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 30.90 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 6.83 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026 provisional experimental data, Surrey residents accounted for 109,530 community care contacts, 66,060 care activities, 33,510 patients with a contact, and 28,700 referrals. Across NHS Surrey and Sussex ICB, contacts totaled 309,615. Adults aged 65+ accounted for 69.6% of borough residents' contacts. These figures capture provider-submitted community activity across local authority residents, not PCN-specific cohorts.
Practice variation and patient experience
Vaccination achievement spans 9.4 percentage points across practices alongside varying personalised care adjustments
In 2025/26, overall QOF achievement was 93.2% at Modality East Surrey Medical Practice and 84.1% at Wayside Medical Practice (England 92.5%). Vaccination and immunisation achievement trailed England (55.2%) at both sites, reaching 44.5% at Modality East Surrey Medical Practice and 35.1% at Wayside Medical Practice, spanning a 9.4 pp range. This gap could reflect call-and-recall differences, which an audit could.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wayside Medical | 85 | 0.0 | 58.3% | 77.3% | 81.3% |
| Modality East | 95 | 0.0 | 63.1% | 86.3% | 75.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across three-year trends, 7 measures trail England despite rapid mental health check gains
Across 25 tracked indicators, 7 measures trail England's three-year change. The widest lags are contracting respiratory registers: COPD prevalence fell 12.2% (England +2.6%) and asthma fell 5.8% (England +0.5%), alongside statin therapy in diabetes with CVD falling 2.6% (England +1.0%). Conversely, severe mental illness checks surged: blood pressure recording rose +25.5 pp to 87.2% (England +4.4 pp) and BMI rose +24.4 pp to 84.7% (England +5.1 pp). Heart failure reviews rose +27.6% to 83.1% (England +8.7%). Prioritising secondary prevention statin reviews and respiratory diagnostic coding could address these divergent trends.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Asthma register
Diabetes statin (CVD)
BP control, 80+
QRISK statin treatment
BP check (SMI)
BMI record (SMI)
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Reigate and Banstead | Asset | PCN | Reigate and Banstead |
|---|---|---|---|---|---|
| Care homes (catchment) | 38 (809 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 4 | 8 | Places of worship | 42 | 70 |
| Libraries | 3 | 6 | Food banks (VCS) | 5 | 6 |
| Homelessness support (VCS) | 2 | 2 | Day centres (VCS) | 8 | 40 |
| Children and young people (VCS) | 3 | 8 | Carers support groups (VCS) | 1 | 6 |
| Primary schools (LA maintained) | 12 | 14 | Primary academies | 8 | 18 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension titration and statin escalation
Hypertension treatment to target is 67.4% across 6,625 patients (England 70.3%, Reigate and Banstead 72.0%), and QRISK ≥ 20% lipid therapy is 52.2% (England 63.6%). For discussion: run pharmacist-led medication titration and statin initiation recalls for patients above blood pressure thresholds or with untreated QRISK ≥ 20%. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma annual review and youth recall
Asthma reviews cover 69.5% of the 2,696 register (leaving 822 unreviewed), while youth second-hand smoke recording is 69.8% (England 78.8%, Reigate and Banstead 79.7%). For discussion: introduce a standardised asthma review recall template with mandatory youth second-hand smoke prompts and after-school appointment slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
COPD register validation and case-finding
COPD prevalence is 1.4% (643 patients), matching Reigate and Banstead (1.4%) but 0.5 pp below England (1.9%), with a benchmark gap range of -28 to +213. For discussion: search for smokers and ex-smokers on repeat respiratory prescribing without a COPD code, and raise diagnostic spirometry capacity with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health equity targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Blood pressure titration audit (p5) | Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening recall and outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Hypertension titration and statin escalation (p12) | Hypertension register · Hypertension patients with a recent BP reading · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Asthma annual review and youth recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · COPD register validation and case-finding (p12) | COPD register · COPD: QOF prevalence · Registered population | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
